Categories Analysis, Technology

Apple could get hurt in the fight against Huawei

The trade war between the US and China is raging on, and amid this, the US blacklisted a prominent Chinese firm, Huawei Technologies Co. Ltd, last week. Even though the US government has provided some temporary relief, the move has sparked outrage in China.

Now it appears this outrage might have a casualty in the form of Apple Inc. (NASDAQ: AAPL). Huawei has been getting plenty of support from Chinese users on social media with many declaring that they would ditch iPhones in favor of Huawei’s products.

While social media sentiment has a minor role to play in the field of hard-core business, a report by Bloomberg states that if China were to respond to the US with a similar ban on Apple’s products, it would hurt the tech giant’s earnings by 29%.

Earlier this month, a study by IDC showed that during the first quarter of 2019, Huawei surpassed Apple both on smartphone shipment volumes and market share. Huawei held a market share of 19% while Apple had only 11.7%. Huawei managed to grow its shipment volumes by 50% year-over-year while Apple’s shipments fell 30%.

Smartphone shipments and volume for Apple, Huawei, Samsung and Xiaomi

In its second-quarter 2019 earnings announcement, Apple said its sales declined 22% year-over-year in Greater China. China is Apple’s third largest market after the Americas and Europe and accounts for a meaningful portion of its revenue.

Apple already faces tough competition in China from Huawei and other local companies and the ongoing spat is likely to worsen the situation for the iPhone-maker in the region.

Apple’s shares were down 1.7% in afternoon hours on Wednesday.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Most Popular

Context Therapeutics: Another clinical-stage oncology research firm to go public soon

The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for

Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?

The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top